Serum Soluble Triggering Receptor Expressed on Myeloid Cells 2 as a Biomarker for Incident Dementia: The Hisayama Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE
    • Publication Information:
      Publication: New York, NY : Wiley-Liss
      Original Publication: Boston, Little, Brown.
    • Subject Terms:
    • Abstract:
      Objective: To investigate the association between serum soluble triggering receptor expressed on myeloid cells 2 (sTREM2), a soluble type of an innate immune receptor expressed on the microglia, and the risk of dementia.
      Methods: A total of 1,349 Japanese community residents aged 60 and older without dementia were followed prospectively for 10 years (2002-2012). Serum sTREM2 levels were quantified by using an enzyme-linked immunosorbent assay and divided into quartiles. Cox proportional hazards model was used to estimate the hazard ratios (HRs) of serum sTREM2 levels on the risk of dementia.
      Results: During the follow-up, 300 subjects developed all-cause dementia; 193 had Alzheimer's disease (AD), and 85 had vascular dementia (VaD). The age- and sex-adjusted incidences of all-cause dementia, AD, and VaD elevated significantly with higher serum sTREM2 levels (all p for trend < 0.012). These associations were not altered after adjustment for confounding factors, including high-sensitive C-reactive protein. Subjects with the highest quartile of serum sTREM2 levels had significantly higher multivariable-adjusted risks of developing all-cause dementia, AD, and VaD than those with the lowest quartile (HR = 2.03, 95% confidence interval [CI] = 1.39-2.97, p < 0.001 for all-cause dementia; HR = 1.62, 95% CI = 1.02-2.55, p = 0.04 for AD; HR = 2.85, 95% CI = 1.35-6.02, p = 0.006 for VaD). No significant heterogeneity in the association of serum sTREM2 levels with the development of dementia was observed among the other risk factor subgroups (all p for heterogeneity > 0.11).
      Interpretation: The present findings suggest a significant association between increased serum sTREM2 levels and the risk of developing all-cause dementia, AD, and VaD in the general elderly Japanese population. ANN NEUROL 2019;85:47-58.
      (© 2018 American Neurological Association.)
    • Grant Information:
      JP18dk0207025 International Japan Agency for Medical Research and Development; JP18ek0210082 International Japan Agency for Medical Research and Development; JP18gm0610007 International Japan Agency for Medical Research and Development; JP18ek0210083 International Japan Agency for Medical Research and Development; JP18km0405202 International Japan Agency for Medical Research and Development; JP18ek0210080 International Japan Agency for Medical Research and Development; JP18fk0108075 International Japan Agency for Medical Research and Development; H29-Junkankitou-Ippan-003 International Ministry of Health, Labor, and Welfare of Japan; H30-Shokuhin-[Sitei]-005 International Ministry of Health, Labor, and Welfare of Japan; JP16H02644 International Scientific Research; JP16H02692 International Scientific Research; JP16H05557 International Scientific Research; JP16H05850 International Scientific Research; JP17H04126 International Scientific Research; JP18H02737 International Scientific Research; JP16K09244 International Scientific Research; JP17K01853 International Scientific Research; JP17K09113 International Scientific Research; JP17K09114 International Scientific Research; JP18K07565 International Scientific Research; JP18K09412 International Scientific Research; JP18K17382 International Early-Career Scientists; JP18K17925 International Early-Career Scientists; International Ministry of Education, Culture, Sports, Science, and Technology of Japan
    • Accession Number:
      0 (Biomarkers)
      0 (Membrane Glycoproteins)
      0 (Receptors, Immunologic)
      0 (TREM2 protein, human)
    • Publication Date:
      Date Created: 20181129 Date Completed: 20191125 Latest Revision: 20191125
    • Publication Date:
      20221213
    • Accession Number:
      10.1002/ana.25385
    • Accession Number:
      30485483